Bristol Myers Squibb Company $BMY Shares Sold by Arvest Bank Trust Division

Arvest Bank Trust Division lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 65.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,374 shares of the biopharmaceutical company’s stock after selling 21,403 shares during the quarter. Arvest Bank Trust Division’s holdings in Bristol Myers Squibb were worth $527,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the business. Trifecta Capital Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $25,000. REAP Financial Group LLC lifted its stake in Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 428 shares in the last quarter. Accent Capital Management LLC acquired a new stake in shares of Bristol Myers Squibb during the first quarter valued at $33,000. CBIZ Investment Advisory Services LLC boosted its stake in shares of Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new stake in Bristol Myers Squibb during the first quarter worth approximately $36,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Trading Down 0.9%

Bristol Myers Squibb stock opened at $48.64 on Friday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The firm has a market capitalization of $99.02 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 2.23 and a beta of 0.33. The firm has a 50-day moving average price of $45.35 and a two-hundred day moving average price of $46.71. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s revenue was up 2.8% compared to the same quarter last year. During the same period last year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were issued a $0.62 dividend. The ex-dividend date was Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 83.78%.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a report on Tuesday, August 5th. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Finally, Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Four analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $54.58.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.